Radiation dose measurement developer VeriTeQ has inked an agreement with North Carolina State University (NCSU) to license patents for its Q Inside SmartMarker and OneDose radiation dosimetry products.
Under terms of the agreement, VeriTeQ will license 24 patents that apply to Q Inside SmartMarker, an implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external-beam treatments, as well as its OneDose external radiation sensing system, which consists of disposable sensors that attach to the patient's skin using a basic adhesive and a scanner that reads the sensor.
Previously, the patents were made available to VeriTeQ through a sublicense agreement. The new, direct agreement with NCSU is effective immediately, according to the firm.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
